| |
 |
Preface [ Hot Topic: Radiation Oncology as Mainstay of Modern Cancer Medicine (Guest Editors: Claus Belka & Verena Jendrossek)]
|
| |
|
pp.ii-ii (1) Authors: Claus Belka, Verena Jendrossek |
| |
|
|
| |
|
Disruption of Cell Death Signaling in Cancer: Impact on Disease Prognosis and Response to Therapy
|
| |
|
pp.319-326 (8) Authors: Dilek Guner, Claus Belka, Peter T. Daniel |
| |
|
|
| |
|
Anti-Epidermal Growth Factor Receptor Strategies to Enhance Radiation Action
|
| |
|
pp.327-333 (7) Author: G. Lammering |
| |
|
|
| |
|
Death Receptor Ligands: New Strategies for Combined Treatment with Ionizing Radiation
|
| |
|
pp.334-342 (9) Authors: Patrizia Marini, Claus Belka |
| |
|
|
| |
|
Membrane Targeted Anticancer Drugs: Potent Inducers of Apoptosis and Putative Radiosensitisers
|
| |
|
pp.343-353 (11) Authors: V. Jendrossek, R. Handrick |
| |
|
|
| |
|
New Targets for the Modulation of Radiation Response - Selective Inhibition of the Enzyme Cyclooxygenase 2
|
| |
|
pp.354-359 (6) Authors: Cordula Petersen, Michael Baumann, Sven Petersen |
| |
|
|
| |
|
Radioprotection of Normal Tissue to Improve Radiotherapy: The Effect of the Bowman Birk Protease Inhibitor
|
| |
|
pp.360-363 (4) Authors: K. H. Dittmann, C. Mayer, H. P. Rodemann |
| |
|
|
| |
|
Hypoxic Radiosensitizers and Hypoxic Cytotoxins in Radiation Oncology
|
| |
|
pp.364-374 (11) Authors: Martin Weinmann, Stefan Welz, Michael Bamberg |
| |
|
|
| |
|
Antiangiogenesis and Radiotherapy: What Is the Role of Combined Modality Treatment?
|
| |
|
pp.375-382 (8) Authors: Johannes Classen, Wilfried Budach |
| |
|
|
